Results 31 to 40 of about 2,154,176 (393)

A comprehensive review of protein kinase inhibitors for cancer therapy

Expert Review of Anticancer Therapy, 2018
Introduction: Protein kinases are involved in various cellular functions. About 2% of the human genome encodes for protein kinases. Dysregulation of protein kinases is implicated in various processes of carcinogenesis.
Radhamani Kannaiyan, D. Mahadevan
semanticscholar   +1 more source

Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway [PDF]

, 2006
We report a multiwavelength (X-ray, ultraviolet/optical/infrared, radio) analysis of the relativistic tidal disruption event candidate Sw J2058+05 from 3 months to 3 yr post-discovery in order to study its properties and compare its behavior with that of
Bower, Geoffrey C., Brown, Gregory C., Cenko, S. Bradley, Dolan, Stephen, Filippenko, Alexei V., Fruchter, Andrew S., Greiner, Jochen, Horesh, Assaf, Hounsell, Rebekah A., Levan, Andrew J., O'Brien, Paul T., Page, Kim L., Pasham, Dheeraj R., Rau, Arne, Tanvir, Nial R., Wiersema, Klaas   +15 more
core   +2 more sources

Depletion of Ca2+ from the sarcoplasmic reticulum of cardiac muscle prompts phosphorylation of phospholamban to stimulate store refilling [PDF]

, 1998
Nonmuscle cells have almost ubiquitously evolved a mechanism to detect and prevent Ca(2+) store depletionstore operated calcium entry. No such mechanism has, as yet, been reported in cardiac myocytes.
Bhogal, M.S., Colyer, J.
core   +2 more sources

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. [PDF]

PLoS ONE, 2017
Protein kinases are critical drug targets for treating a large variety of human diseases. Type-III kinase inhibitors have attracted increasing attention as highly selective therapeutics.
Zheng Zhao, Lei Xie, Philip E Bourne
doaj   +1 more source

Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]

, 2020
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGFβ
A Rojas-Fernandez, A Woods, AR Ramjaun, AY Hsing, B Bierie, B Ozdamar, B-C Kim, BR Binder, C Allan, CJ David, CS Hill, DB Shackelford, EC Connolly, FA Ran, G Avery-Cooper, G Rena, G Rosti, GD Cuny, GJ Inman, GJ Inman, GM Keating, H Ikushima, J Massagué, J Massagué, J Massaous, J Ozanne, J Song, J Vogt, J Xu, JF Callahan, JL Wrana, JM Lizcano, Joan Massagué, JY Altarejos, K Clark, KA Brown, KJ Livak, LC Spender, LC Spender, M Abe, M Kowanetz, M Tojo, MO Li, MR Keeton, NJ Bright, P Lönn, PH Lin, PK Datta, PM Siegel, RJ Akhurst, RJ Akhurst, S DaCosta Byfield, S Dennler, S Edlund, S Strickson, SA Hawley, T Sonntag, TB Sundberg, Y Drabsch, Y Liu, Y Shi, Y Yang, Y Zhang, Y Zhang   +63 more
core   +2 more sources

Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study

European Respiratory Journal, 2019
The pathophysiology of pulmonary arterial hypertension (PAH) induced by protein kinase inhibitors (PKIs) remains unclear. To gain knowledge into this rare and severe pathology we performed a study combining a pharmacovigilance approach and the ...
Lucie Cornet, C. Khouri, M. Roustit, C. Guignabert, M. Chaumais, M. Humbert, B. Revol, F. Despas, D. Montani, J. Cracowski   +9 more
semanticscholar   +1 more source

Identification of inactive conformation‐selective interleukin‐2‐inducible T‐cell kinase (ITK) inhibitors based on second‐harmonic generation

FEBS Open Bio, 2018
Many clinically approved protein kinase inhibitors stabilize an inactive conformation of their kinase target. Such inhibitors are generally highly selective compared to active conformation inhibitors, and consequently, general methods to identify ...
Yoshiji Hantani, Kiyosei Iio, Rie Hantani, Kayo Umetani, Toshihiro Sato, Tracy Young, Katelyn Connell, Sam Kintz, Joshua Salafsky   +8 more
doaj   +1 more source

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

BMC Medicine, 2012
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD.
Rudenko Iakov N, Chia Ruth, Cookson Mark R   +2 more
doaj   +1 more source

Investigating the effect of target of rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets [PDF]

, 2019
Recuperado de: https://www.biorxiv.org/content/10.1101/310102v1Target of rapamycin (TOR) kinase is a conserved regulator of cell growth whose activity is modulated in response to nutrients, energy and stress.
Couso Liáñez, Inmaculada Concepción, Crespo González, José Luis, Hicks, Leslie, McConnell, Evan W., Perrine, Zoee, Umen, James G., Werth, Emily G.   +6 more
core   +1 more source

Targeting mTOR for cancer therapy

Journal of Hematology & Oncology, 2019
Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2).
Hui Hua, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo, Yangfu Jiang   +5 more
doaj   +1 more source